210 related articles for article (PubMed ID: 38481815)
21. Discovery of a peripheral 5HT
Pagire HS; Pagire SH; Jeong BK; Choi WI; Oh CJ; Lim CW; Kim M; Yoon J; Kim SS; Bae MA; Jeon JH; Song S; Lee HJ; Lee EY; Goughnour PC; Kim D; Lee IK; Loomba R; Kim H; Ahn JH
Nat Commun; 2024 Jan; 15(1):645. PubMed ID: 38245505
[TBL] [Abstract][Full Text] [Related]
22. TM7SF3 controls TEAD1 splicing to prevent MASH-induced liver fibrosis.
Isaac R; Bandyopadhyay G; Rohm TV; Kang S; Wang J; Pokhrel N; Sakane S; Zapata R; Libster AM; Vinik Y; Berhan A; Kisseleva T; Borok Z; Zick Y; Telese F; Webster NJG; Olefsky JM
Cell Metab; 2024 May; 36(5):1030-1043.e7. PubMed ID: 38670107
[TBL] [Abstract][Full Text] [Related]
23. Cancer-Associated Mutations of the Adenosine A
Feng C; Wang X; Jespers W; Liu R; Zamarbide Losada SD; Gorostiola González M; van Westen GJP; Danen EHJ; Heitman LH
Molecules; 2022 Jul; 27(15):. PubMed ID: 35897852
[TBL] [Abstract][Full Text] [Related]
24. Adenosine A2A receptor activation reduces infarct size in the isolated, perfused mouse heart by inhibiting resident cardiac mast cell degranulation.
Rork TH; Wallace KL; Kennedy DP; Marshall MA; Lankford AR; Linden J
Am J Physiol Heart Circ Physiol; 2008 Nov; 295(5):H1825-33. PubMed ID: 18757481
[TBL] [Abstract][Full Text] [Related]
25. A high-cholesterol diet exacerbates liver fibrosis in mice via accumulation of free cholesterol in hepatic stellate cells.
Teratani T; Tomita K; Suzuki T; Oshikawa T; Yokoyama H; Shimamura K; Tominaga S; Hiroi S; Irie R; Okada Y; Kurihara C; Ebinuma H; Saito H; Hokari R; Sugiyama K; Kanai T; Miura S; Hibi T
Gastroenterology; 2012 Jan; 142(1):152-164.e10. PubMed ID: 21995947
[TBL] [Abstract][Full Text] [Related]
26. Hydrogen-rich water protects against liver injury in nonalcoholic steatohepatitis through HO-1 enhancement via IL-10 and Sirt 1 signaling.
Li SW; Takahara T; Que W; Fujino M; Guo WZ; Hirano SI; Ye LP; Li XK
Am J Physiol Gastrointest Liver Physiol; 2021 Apr; 320(4):G450-G463. PubMed ID: 33439102
[TBL] [Abstract][Full Text] [Related]
27. Hepatocyte-specific CCAAT/enhancer binding protein α restricts liver fibrosis progression.
Yan T; Yan N; Xia Y; Sawaswong V; Zhu X; Dias HB; Aibara D; Takahashi S; Hamada K; Saito Y; Li G; Liu H; Yan H; Velenosi TJ; Krausz KW; Huang J; Kimura S; Rotman Y; Qu A; Hao H; Gonzalez FJ
J Clin Invest; 2024 Apr; 134(7):. PubMed ID: 38557493
[TBL] [Abstract][Full Text] [Related]
28. Water extract of earthworms mitigates mouse liver fibrosis by potentiating hepatic LKB1/Nrf2 axis to inhibit HSC activation and hepatocyte death.
Zhang T; Wang C; Song A; Lei X; Li G; Sun H; Wang X; Geng Z; Shu G; Deng X
J Ethnopharmacol; 2024 Mar; 321():117495. PubMed ID: 38016572
[TBL] [Abstract][Full Text] [Related]
29. Neutrophil extracellular traps activate hepatic stellate cells and monocytes via NLRP3 sensing in alcohol-induced acceleration of MASH fibrosis.
Babuta M; Morel C; de Carvalho Ribeiro M; Calenda C; Ortega-Ribera M; Thevkar Nagesh P; Copeland C; Zhuang Y; Wang Y; Cho Y; Joshi R; Brezani V; Hawryluk D; Datta AA; Mehta J; Nasser I; Szabo G
Gut; 2024 May; ():. PubMed ID: 38777573
[TBL] [Abstract][Full Text] [Related]
30. Adenosine A(2A) receptors play a role in the pathogenesis of hepatic cirrhosis.
Chan ES; Montesinos MC; Fernandez P; Desai A; Delano DL; Yee H; Reiss AB; Pillinger MH; Chen JF; Schwarzschild MA; Friedman SL; Cronstein BN
Br J Pharmacol; 2006 Aug; 148(8):1144-55. PubMed ID: 16783407
[TBL] [Abstract][Full Text] [Related]
31. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis.
Yamaguchi K; Yang L; McCall S; Huang J; Yu XX; Pandey SK; Bhanot S; Monia BP; Li YX; Diehl AM
Hepatology; 2007 Jun; 45(6):1366-74. PubMed ID: 17476695
[TBL] [Abstract][Full Text] [Related]
32. Reduced coronary reactive hyperemia in mice was reversed by the soluble epoxide hydrolase inhibitor (t-AUCB): Role of adenosine A
Hanif A; Edin ML; Zeldin DC; Morisseau C; Falck JR; Ledent C; Tilley SL; Nayeem MA
Prostaglandins Other Lipid Mediat; 2017 Jul; 131():83-95. PubMed ID: 28890385
[TBL] [Abstract][Full Text] [Related]
33. An improved mouse model that rapidly develops fibrosis in non-alcoholic steatohepatitis.
Matsumoto M; Hada N; Sakamaki Y; Uno A; Shiga T; Tanaka C; Ito T; Katsume A; Sudoh M
Int J Exp Pathol; 2013 Apr; 94(2):93-103. PubMed ID: 23305254
[TBL] [Abstract][Full Text] [Related]
34. Liver fatty acid binding protein (L-Fabp) modulates murine stellate cell activation and diet-induced nonalcoholic fatty liver disease.
Chen A; Tang Y; Davis V; Hsu FF; Kennedy SM; Song H; Turk J; Brunt EM; Newberry EP; Davidson NO
Hepatology; 2013 Jun; 57(6):2202-12. PubMed ID: 23401290
[TBL] [Abstract][Full Text] [Related]
35. Adenosine A2A receptor activation reduces recurrence and mortality from Clostridium difficile infection in mice following vancomycin treatment.
Li Y; Figler RA; Kolling G; Bracken TC; Rieger J; Stevenson RW; Linden J; Guerrant RL; Warren CA
BMC Infect Dis; 2012 Dec; 12():342. PubMed ID: 23217055
[TBL] [Abstract][Full Text] [Related]
36. Administration of the potent PPARalpha agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice.
Ip E; Farrell G; Hall P; Robertson G; Leclercq I
Hepatology; 2004 May; 39(5):1286-96. PubMed ID: 15122757
[TBL] [Abstract][Full Text] [Related]
37. Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis.
Witek RP; Stone WC; Karaca FG; Syn WK; Pereira TA; Agboola KM; Omenetti A; Jung Y; Teaberry V; Choi SS; Guy CD; Pollard J; Charlton P; Diehl AM
Hepatology; 2009 Nov; 50(5):1421-30. PubMed ID: 19676126
[TBL] [Abstract][Full Text] [Related]
38. Elevated expression of LCN13 through FXR activation ameliorates hepatocellular lipid accumulation and inflammation.
Qin X; Tan Y; Ren W; Zhou W; Niu R; Liang L; Li J; Cao K; Wei G; Zhu X; Huang M
Int Immunopharmacol; 2024 Apr; 131():111812. PubMed ID: 38493698
[TBL] [Abstract][Full Text] [Related]
39. Antioxidative Hyaluronic Acid-Bilirubin Nanomedicine Targeting Activated Hepatic Stellate Cells for Anti-Hepatic-Fibrosis Therapy.
Shinn J; Park S; Lee S; Park N; Kim S; Hwang S; Moon JJ; Kwon Y; Lee Y
ACS Nano; 2024 Feb; 18(6):4704-4716. PubMed ID: 38288705
[TBL] [Abstract][Full Text] [Related]
40. Adenosine A
Hanif A; Agba SO; Ledent C; Tilley SL; Morisseau C; Nayeem MA
Mol Cell Biochem; 2021 May; 476(5):1965-1978. PubMed ID: 33511551
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
